Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

TENK

TenX Keane Acquisition

Jun 21 • 04:00PM ET

11.36

Dollar change +0.02
Percentage change 0.18	%

Financial • Shell Companies • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	41.28	EPS (ttm)	0.28	Insider Own	68.71%	Shs Outstand	13.65M	Perf Week	0.09%
Market Cap	155.06M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.27M	Perf Month	1.97%
Income	2.30M	PEG	-	EPS next Q	-	Inst Own	31.21%	Short Float	0.01%	Perf Quarter	3.65%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.03	Perf Half Y	6.87%
Book/sh	-0.37	P/B	-	EPS next Y	-	ROA	3.91%	Short Interest	0.00M	Perf Year	-
Cash/sh	0.00	P/C	5168.80	EPS next 5Y	-	ROE	4.01%	52W Range	10.50 - 12.03	Perf YTD	3.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	5.01%	52W High	-5.57%	Beta	-0.02
Dividend TTM	-	Quick Ratio	0.03	Sales past 5Y	0.00%	Gross Margin	-	52W Low	8.19%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	0.03	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	76.41	Volatility	0.04% 0.70%
Employees	-	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	8.39%	Payout	0.00%	Rel Volume	0.59	Prev Close	11.34
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	12.68K	Price	11.36
SMA20	0.65%	SMA50	1.86%	SMA200	5.83%	Trades		Volume	7,440	Change	0.18%

May-14-24 04:05PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Feb-14-24 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Jan-10-24 02:29PM	TenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment Proposal (GlobeNewswire)
Oct-24-23 07:30AM	Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. (PR Newswire)
Oct-18-23 04:00PM	TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination (GlobeNewswire)
04:00PM	Loading…
Jul-18-23 04:00PM	TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination (GlobeNewswire)

TenX Keane Acquisition is a blank check company, which engages in the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The company was founded on March 1, 2021 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TENK

TenX Keane Acquisition

Upgrade your FINVIZ experience